Home Sitemap Contact us Accessibility Statement Top of the page
  • Myocet® (liposomal doxorubicin) Teva

    Myocet®

    (liposomal doxorubicin)

Prescribing Myocet®

Myocet® (liposomal doxorubicin) 50mg powder, dispersion and solvent for concentrate for dispersion for infusion

Therapeutic indications

Myocet®, in combination with cyclophosphamide, is indicated for the first line treatment of metastatic breast cancer in adult women.1

About Myocet®

Myocet® is a powder, dispersion and solvent for concentrate for dispersion for infusion.
Myocet® is supplied as a three-vial system:

  • Myocet® doxorubicin HCl is a red lyophilised powder
  • Myocet® liposomes is a white to off-white, opaque and homogeneous dispersion
  • Myocet® buffer is a clear colourless solution1

Marketing Authorisation

TEVA B.V.
Swensweg 5
2031 GA Haarlem
Netherlands

Marketing Authorisation Number(s)

  • EU/1/00/141/001-002

Resources for Myocet®

You can ask a question, request to see a representative from Teva, or report a side effect.

Ask a Question Request a Rep Report Suspected Side Effect
Medicine supporting documentation for Myocet®
1 Myocet® (liposomal doxorubicin) Summary of Product Characteristics.

Teva UK Limited

Are you a healthcare professional?

To access this section of the Teva UK Limited website you need to be a member of the healthcare profession because the materials included in this area of our website are specifically prepared for that audience only.
To understand why that is - please visit: Working in a regulated environment

Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.

I am a